Skip to main content
SpringerLink
Log in

Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group

  • Guidelines
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

The TheraSphere Global Dosimetry Steering Committee was formed in 2017 by BTG International to review existing data and address gaps in knowledge related to dosimetry. This committee is comprised of health care providers with diverse areas of expertise and perspectives on radiation dosimetry. The goal of these recommendations is to optimize glass microspheres radiation therapy for hepatocellular carcinoma while accounting for variables including disease presentation, tumour vascularity, liver function, and curative/palliative intent. The recommendations aim to unify glass microsphere users behind standardized dosimetry methodology that is simple, reproducible and supported by clinical data, with the overarching goal of improving clinical outcomes and advancing the knowledge of dosimetry.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gaba RC, Lokken RP, Hickey RM, Lipnik AJ, Lewandowski RJ, Salem R, et al. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. J Vasc Interv Radiol: JVIR. 2017. https://doi.org/10.1016/j.jvir.2017.04.025.

  2. Benson AB, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, et al. Hepatobiliary cancers, version 2.2014. J Natl Compr Cancer Netw. 2014;12:1152–82.

    Article  CAS  Google Scholar 

  3. Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151:1155–63.e2. https://doi.org/10.1053/j.gastro.2016.08.029.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Yttrium S-S. Resin microspheres [package insert]. North Sydney. Australia: SirTex Medical; 2013.

    Google Scholar 

  5. BTG. Insert–TheraSphere P. Yttrium-90 glass microspheres–rev. 12. Biocompatibles UK Ltd, a BTG international group company.

  6. Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guerriero F, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;4:210. https://doi.org/10.3389/fonc.2014.00210.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Poree P, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057–68. https://doi.org/10.1007/s00259-013-2395-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Garin E, Rolland Y, Edeline J, Icard N, Lenoir L, Laffont S, et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med: Off Publ, Soc Nucl Med. 2015;56:339–46. https://doi.org/10.2967/jnumed.114.145177.

    Article  CAS  Google Scholar 

  9. Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A. Hepatocellular carcinoma tumor dose response after (90)Y-radioembolization with glass microspheres using (90)Y-SPECT/CT-based voxel dosimetry. Int J Radiat Oncol Biol Phys. 2018;102:451–61. https://doi.org/10.1016/j.ijrobp.2018.05.062.

    Article  PubMed  Google Scholar 

  10. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clin Res ed). 2008;336:924–6. https://doi.org/10.1136/bmj.39489.470347.AD.

    Article  Google Scholar 

  11. Gates VL, Singh N, Lewandowski RJ, Spies S, Salem R. Intraarterial hepatic SPECT/CT imaging using 99mTc-macroaggregated albumin in preparation for radioembolization. J Nucl Med: Off Publ, Soc Nucl Med. 2015;56:1157–62. https://doi.org/10.2967/jnumed.114.153346.

    Article  CAS  Google Scholar 

  12. Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur J Nucl Med Mol Imaging. 2016;43:559–75. https://doi.org/10.1007/s00259-015-3157-8.

    Article  CAS  PubMed  Google Scholar 

  13. Chiesa C, Lambert B, Maccauro M, Ezziddin S, Ahmadzadehfar H, Dieudonne A, et al. Pretreatment dosimetry in HCC radioembolization with (90)Y glass microspheres cannot be invalidated with a bare visual evaluation of (99m)Tc-MAA uptake of colorectal metastases treated with resin microspheres. J Nucl Medi: Off Publ Soc Nucl Med. 2014;55:1215–6. https://doi.org/10.2967/jnumed.113.129361.

    Article  Google Scholar 

  14. Ulrich G, Dudeck O, Furth C, Ruf J, Grosser OS, Adolf D, et al. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres. J Nucl Medi: Off Publ Soc Nucl Med. 2013;54:516–22. https://doi.org/10.2967/jnumed.112.112508.

    Article  CAS  Google Scholar 

  15. Chan K, Alessio A, Johnson G, Vaidya S, Kwan S, Monsky W, et al. Prospective trial using internal pair-production positron emission tomography to establish the Yttrium-90 radioembolization dose required for response of hepatic tumors. Int J Radiat Oncol Biol Phys. 2018;101(2):358–365.

  16. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Medi: Off Publ Soc Nucl Med. 2009;50:477–84. https://doi.org/10.2967/jnumed.108.056036.

    Article  CAS  Google Scholar 

  17. International Commission on Radiation Units and Measurements.. Report 85. Fundamental quantities and units for ionizing radiation. J ICRU. 2011;11:1–31. https://doi.org/10.1093/jicru/ndr011.

  18. Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Medi: Off Publ Soc Nucl Med. 2006;47:1209–11.

    CAS  Google Scholar 

  19. Dezarn WA, Cessna JT, DeWerd LA, Feng W, Gates VL, Halama J, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011;38:4824–45. https://doi.org/10.1118/1.3608909.

    Article  PubMed  Google Scholar 

  20. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol: JVIR. 2002;13:S223–9.

    Article  PubMed  Google Scholar 

  21. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol: JVIR. 2006;17:1251–78. https://doi.org/10.1097/01.rvi.0000233785.75257.9a.

    Article  PubMed  Google Scholar 

  22. Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol: JVIR. 2006;17:1425–39. https://doi.org/10.1097/01.rvi.0000235779.88652.53.

    Article  PubMed  Google Scholar 

  23. Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287:1050–8. https://doi.org/10.1148/radiol.2018171768.

  24. Padia SA, Johnson GE, Horton KJ, Ingraham CR, Kogut MJ, Kwan S, et al. Segmental Yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. J Vasc Interv Radiol: JVIR. 2017;28:777–85.e1. https://doi.org/10.1016/j.jvir.2017.02.018.

    Article  PubMed  Google Scholar 

  25. Biederman DM, Titano JJ, Bishay VL, Durrani RJ, Dayan E, Tabori N, et al. Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study. Radiology. 2016:160718. https://doi.org/10.1148/radiol.2016160718.

  26. Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79:163–71. https://doi.org/10.1016/j.ijrobp.2009.10.062.

    Article  PubMed  Google Scholar 

  27. Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol: JVIR. 2014;25:1067–73. https://doi.org/10.1016/j.jvir.2014.03.030.

    Article  PubMed  Google Scholar 

  28. Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatol (Baltimore, Md). 2014;60:192–201. https://doi.org/10.1002/hep.27057.

    Article  Google Scholar 

  29. Ali R, Riaz A, Gabr A, Abouchaleh N, Mora R, Al Asadi A, et al. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. Eur J Nucl Med Mol Imaging. 2017;44:2195–202. https://doi.org/10.1007/s00259-017-3792-3.

    Article  PubMed  Google Scholar 

  30. Johnson GE, Monsky WL, Valji K, Hippe DS, Padia SA. Yttrium-90 Radioembolization as a salvage treatment following chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol: JVIR. 2016;27:1123–9. https://doi.org/10.1016/j.jvir.2016.03.046.

    Article  PubMed  Google Scholar 

  31. Gates VL, Hickey R, Marshall K, Williams M, Salzig K, Lewandowski RJ, et al. Gastric injury from 90Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction? Eur J Nucl Med Mol Imaging. 2015;42:2038–44. https://doi.org/10.1007/s00259-015-3122-6.

    Article  PubMed  Google Scholar 

  32. Atassi B, Bangash AK, Bahrani A, Pizzi G, Lewandowski RJ, Ryu RK, et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiograph: Rev Publ Radiol Soc North Am, Inc. 2008;28:81–99. https://doi.org/10.1148/rg.281065721.

    Article  Google Scholar 

  33. Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol. 2012;57:421–9. https://doi.org/10.1016/j.jhep.2012.01.031.

    Article  PubMed  Google Scholar 

  34. Louie JD, Kothary N, Kuo WT, Hwang GL, Hofmann LV, Goris ML, et al. Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. J Vasc Interv Radiol: JVIR. 2009;20:606–13. https://doi.org/10.1016/j.jvir.2009.01.021.

    Article  PubMed  Google Scholar 

  35. Hamoui N, Minocha J, Memon K, Sato K, Ryu R, Salem R, et al. Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres. J Vasc Interv Radiol. 2013;24:1743–5. https://doi.org/10.1016/j.jvir.2013.07.011.

    Article  PubMed  Google Scholar 

  36. Kallini JR, Gabr A, Kulik L, Salem R, Lewandowski RJ. The utility of unilobar technetium-99m macroaggregated albumin to predict pulmonary toxicity in bilobar hepatocellular carcinoma prior to Yttrium-90 radioembolization. J Vasc Interv Radiol. 2016;27:1453–6. https://doi.org/10.1016/j.jvir.2016.06.004.

    Article  PubMed  Google Scholar 

  37. Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA, Kulik L, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571–92. https://doi.org/10.1007/s00270-007-9064-z.

    Article  PubMed  Google Scholar 

  38. Gabr A, Kallini JR, Gates VL, Hickey R, Kulik L, Desai K, et al. Same-day 90Y radioembolization: implementing a new treatment paradigm. Eur J Nucl Med Mol Imaging. 2016;43:2353–9. https://doi.org/10.1007/s00259-016-3438-x.

    Article  CAS  PubMed  Google Scholar 

  39. Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology. 2011;141:526–35.e2. https://doi.org/10.1053/j.gastro.2011.04.054.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Riaz A, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora R, et al. Radioembolization for hepatocellular carcinoma: statistical confirmation of improved survival in responders by landmark analyses. Hepatol (Baltimore, Md). 2018;67:873–83. https://doi.org/10.1002/hep.29480.

    Article  Google Scholar 

  41. Lewandowski RJ, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, et al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114:99–105. https://doi.org/10.1002/jso.24269.

    Article  PubMed  Google Scholar 

  42. Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59:1029–36. https://doi.org/10.1016/j.jhep.2013.06.015.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Braat M, de Jong HW, Seinstra BA, Scholten MV, van den Bosch M, Lam M. Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients. EJNMMI Res. 2017;7:2. https://doi.org/10.1186/s13550-016-0248-x.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Palard X, Edeline J, Rolland Y, Le Sourd S, Pracht M, Laffont S, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2017;45(3):392-401. https://doi.org/10.1007/s00259-017-3845-7.

  45. Spreafico C, Maccauro M, Mazzaferro V, Chiesa C. The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). Eur J Nucl Med Mol Imaging. 2014;41:634–8. https://doi.org/10.1007/s00259-013-2674-6.

    Article  PubMed  Google Scholar 

  46. Edeline J, Lenoir L, Boudjema K, Rolland Y, Boulic A, Le Du F, et al. Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol. 2013;20:2518–25. https://doi.org/10.1245/s10434-013-2906-9.

    Article  PubMed  Google Scholar 

  47. Vouche M, Degrez T, Bouazza F, Delatte P, Galdon MG, Hendlisz A, et al. Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma. World J Hepatol. 2017;9:1372–7. https://doi.org/10.4254/wjh.v9.i36.1372.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Chiesa C, Maccauro M, Romito R, Spreafico C, Pellizzari S, Negri A, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Quart J Nucl Med Mol Imaging : Off Publ Italian Assoc Nucl Med (AIMN) [and] Int Assoc Radiopharmacol (IAR), [and] Sect So. 2011;55:168–97.

    CAS  Google Scholar 

  49. Chan KT, Alessio AM, Johnson GE, Vaidya S, Kwan SW, Monsky W, et al. Hepatotoxic dose thresholds by positron-emission tomography after Yttrium-90 Radioembolization of liver tumors: a prospective single-arm observational study. Cardiovasc Intervent Radiol. 2018;41(9):1363-1372. https://doi.org/10.1007/s00270-018-1949-5.

  50. Gil-Alzugaray B, Chopitea A, Inarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatol (Baltimore, Md). 2013;57:1078–87. https://doi.org/10.1002/hep.26191.

    Article  CAS  Google Scholar 

  51. Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, et al. Institutional decision to adopt Y90 as primary treatment for HCC informed by a 1,000-patient 15-year experience. Hepatol (Baltimore, Md). 2017. https://doi.org/10.1002/hep.29691.

  52. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52–64. https://doi.org/10.1053/j.gastro.2009.09.006.

    Article  CAS  PubMed  Google Scholar 

  53. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatol (Baltimore, Md). 2013;57:1826–37. https://doi.org/10.1002/hep.26014.

    Article  CAS  Google Scholar 

  54. Haste P, Tann M, Persohn S, LaRoche T, Aaron V, Mauxion T, et al. Correlation of technetium-99m macroaggregated albumin and Yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission CT and posttreatment positron emission tomography/CT. J Vasc Interv Radiol: JVIR. 2017;28:722–30.e1. https://doi.org/10.1016/j.jvir.2016.12.1221.

    Article  PubMed  Google Scholar 

  55. Balagopal A, Kappadath C. Characterization of 90Y-SPECT/CT self-calibration approaches on the quantification of voxel-level absorbed doses following 90Y-microsphere selective internal radiation therapy. Med Phys. 2017. https://doi.org/10.1002/mp.12695.

  56. Chiesa C, Mira M, Maccauro M, Spreafico C, Romito R, Morosi C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging. 2015;42:1718–38. https://doi.org/10.1007/s00259-015-3068-8.

    Article  CAS  PubMed  Google Scholar 

  57. Garin E, Rolland Y, Pracht M, Le Sourd S, Laffont S, Mesbah H, et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with. Liver Int. 2017;37:101–10. https://doi.org/10.1111/liv.13220.

    Article  CAS  PubMed  Google Scholar 

  58. Seidensticker R, Seidensticker M, Damm R, Mohnike K, Schütte K, Malfertheiner P, et al. Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach. Cardiovasc Intervent Radiol. 2012;35:1109–18. https://doi.org/10.1007/s00270-011-0295-7.

    Article  PubMed  Google Scholar 

  59. Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, et al. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol. 2017;27:526–35. https://doi.org/10.1007/s00330-016-4445-9.

    Article  PubMed  Google Scholar 

  60. Abouchaleh N, Gabr A, Ali R, Al Asadi A, Mora RA, Kallini JR, et al. Y90 Radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort. J Nucl Medi: Off Publ Soc Nucl Med. 2017. https://doi.org/10.2967/jnumed.117.199752.

  61. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624–36. https://doi.org/10.1016/s1470-2045(17)30683-6.

    Article  CAS  PubMed  Google Scholar 

  62. Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus Sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2018;36:1913–21. https://doi.org/10.1200/jco.2017.76.0892.

    Article  CAS  Google Scholar 

  63. Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol. 2013;58:73–80. https://doi.org/10.1016/j.jhep.2012.09.003.

    Article  PubMed  Google Scholar 

  64. Mikell JK, Mahvash A, Siman W, Baladandayuthapani V, Mourtada F, Kappadath SC. Selective internal radiation therapy with Yttrium-90 glass microspheres: biases and uncertainties in absorbed dose calculations between clinical dosimetry models. Int J Radiat Oncol Biol Phys. 2016;96:888–96. https://doi.org/10.1016/j.ijrobp.2016.07.021.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Ho CL, Chen S, Cheung SK, Leung YL, Cheng KC, Wong KN, et al. Radioembolization with (90)Y glass microspheres for hepatocellular carcinoma: significance of pretreatment (11)C-acetate and (18)F-FDG PET/CT and posttreatment (90)Y PET/CT in individualized dose prescription. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4064-6.

Download references

Funding

This guideline document was not funded.

Author information

Authors and Affiliations

  1. Department of Radiology, Northwestern University, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA

    Riad Salem

  2. Department of Radiology, University of California-Los Angeles, Los Angeles, CA, USA

    Siddharth A. Padia

  3. Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands

    Marnix Lam

  4. Department of Radiology, The Christie, Manchester, UK

    Jon Bell

  5. Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumouri, Milan, Italy

    Carlo Chiesa

  6. BTG International, West Conshohocken, PA, USA

    Kirk Fowers & Bonnie Hamilton

  7. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Joseph Herman

  8. Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    S. Cheenu Kappadath

  9. Comprehensive Oncology Centre, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong

    Thomas Leung

  10. Department of Radiation Oncology, University of Miami, Miami, FL, USA

    Lorraine Portelance

  11. Department of Radiology, Stanford University School of Medicine, Palo Alto, CA, USA

    Daniel Sze

  12. Univ Rennes, INSERM, INRA, Centre de Lutte contre le Cancer Eugène Marquis, Institut NUMECAN (Nutrition Metabolisms and Cancer), F-35000, Rennes, France

    Etienne Garin

Authors
  1. Riad Salem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Siddharth A. Padia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marnix Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jon Bell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carlo Chiesa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kirk Fowers
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bonnie Hamilton
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joseph Herman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Cheenu Kappadath
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Thomas Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lorraine Portelance
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Daniel Sze
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Etienne Garin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Riad Salem.

Ethics declarations

Conflict of interest

All authors are advisors to BTG. Carlo Chiesa received a grant for research and sponsorship for participation to European congresses by BTG. Marnix Lam is an advisor to Terumo and receives research support from BTG, Terumo, Quirem and AAA.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salem, R., Padia, S.A., Lam, M. et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 46, 1695–1704 (2019). https://doi.org/10.1007/s00259-019-04340-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-019-04340-5

Keywords

Search

Navigation